Long-Covid may not be as fatal and hard-hitting as acute COVID-19 and mostly improve over time but it can worsen existing ailments such as diabetes and kidney diseases, healthcare experts said.
The criteria to objectively define long-COVID is still evolving, but WHO recently described it as a post-COVID-19 condition in individuals with a history of probable or confirmed SARS CoV-2 along with symptoms lasting for at least two months and cannot be explained by an alternative diagnosis.
Dr Khan Amir Maroof, Professor at Department of Community Medicine, and Coordinator of Medical Education Unit, University College of Medical Sciences and GTB Hospital, Delhi, said some patients were getting readmitted even after recovery or seeking OPD consultation for Covid-related problems.
"We know that it (long-Covid) is a real entity which we have to keep a track of in our research and clinical practice in the long run. Its effect on the quality of life and the economic status of a family and a community is also to be understood better," Dr Maroof told PTI.
He said various terms -- post-COVID, post-acute-COVID syndrome, chronic-Covid -- are being used to identify COVID-19 manifestations which either persist for two to three months and longer or develop later.
About the repercussions of the long-COVID, he said it is not as fatal and hard-hitting as acute COVID-19 and mostly found to improve over time.
"The symptoms are usually mild to moderate, such as fatigue, shortness of breath, difficulty in concentrating, joint pains, hair loss, and others.
"But the deterioration of quality of life of these patients is worrisome. From a public health perspective, the disability-adjusted life years burden and economic repercussions could be high, which needs to be studied more," he said.
Dr Shibu Vijayan, Global TB Technical Director at Programme for Appropriate Technology in Health, said long-Covid is not worse than COVID-19 but can worsen existing ailments like diabetes and kidney disease or result in precipitation of these diseases or infectious diseases like tuberculosis.
"We are seeing more TB cases post-COVID. The Government has issued guidance to target and aggressively look for tuberculosis among post-Covid," he said.
Dr Vijayan said from Indian studies, it looks like around 30 per cent of the hospitalized cases had long-Covid symptoms, such as fatigue, cough, chest tightness, breathlessness, palpitations, myalgia and difficulty to focus.
"It could be related to organ damage, post-viral syndrome, post-critical care syndrome and others," he said.
About the effectiveness of vaccines against long-COVID, Dr Arunesh Kumar, senior consultant and head of pulmonology at Paras Hospitals in Gurgaon said about half of people with long-COVID reported an improvement in their symptoms after getting the vaccine.
"Getting a jab can reset immune response in long-COVID or help the body attack any remaining fragments of the virus," Dr Kumar said.
Dr Maroof also said that preventing Covid will prevent long-Covid too.
"So, in a way, a vaccine is the key intervention for long-Covid too. Furthermore, some recent studies have shown that those vaccinated have lower intensity and duration of long-COVID as compared to the unvaccinated. So, initial results are promising," Dr Maroof said.
About the line of treatment of long-COVID, Dr Kumar said a specific treatment in near the future is expected when the actual reason or mechanism of the disease is known.
"However, the treatment should be multidisciplinary in nature, including primary care provider as well as relevant specialist rehab professionals, social care workers, psychosocial workers, mental health professionals," he said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)